Avalyn Pharma Inc.

Avalyn Pharma Inc.이(가) 2026년 8월 12일에 보고한 내용

기업이 직접 제출한 8-K에서 가져왔습니다.

실적 발표 컨퍼런스 콜

Avalyn Pharma Inc.의 실적 발표 콜 녹취록이 없습니다.

경영진의 발언

“Completing global enrollment in MIST marks a significant milestone for Avalyn, and the degree of over-enrollment in this study is a testament to the high level of interest from investigators and patients,”

발표 자료에서 그대로 인용했으며, 공시가 발언자를 실명으로 밝힌 경우에만 표시합니다.

주가는 어떻게 반응했나

실적 발표는 장 마감 후나 개장 전에 나오므로, 여기서 말하는 변동은 그다음 거래일입니다.

Avalyn Pharma Inc.은(는) 무엇을 하는 기업인가

Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has indicated encouraging safety and clinical activity across Phase 1b and multi-year open-label extension trials, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies.

발표 자료 말미에 실린 기업 자신의 소개글입니다.